Sotabase

Career

· Sr. Software Engineer, Systems Optimization & Modeling, Tesla2024–
· Data Scientist, Cruise2023–2023
· Graduate Student Researcher, Bits & Watts, Stanford University2018–
· M.S., Electrical Engineering, Stanford University2018–2020
· Researcher, PhD Candidate, Stanford University2018–
· B.S., Energy Engineering, University of California, Berkeley2014–2018
· Tesla

Publications (54)

Hyperalgesia in opioid-managed chronic pain and opioid-dependent patients.
Journal of Pain · 2009
165
cited
Measuring blood-brain barrier penetration using the NeuroCart, a CNS test battery.
Drug Discovery Today : Technologies · 2016
56
cited
Respiratory Effects of the Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist, Cebranopadol, in Healthy Human Volunteers
Anesthesiology · 2017
55
cited
Two Studies on Reversal of Opioid-induced Respiratory Depression by BK-channel Blocker GAL021 in Human Volunteers
Anesthesiology · 2014
47
cited
Lack of Detection of the Analgesic Properties of PF‐05089771, a Selective Nav1.7 Inhibitor, Using a Battery of Pain Models in Healthy Subjects
Clinical and Translational Science · 2019
44
cited
Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial.
Drug Discovery Today · 2020
42
cited
Effects of a single, oral 60 mg caffeine dose on attention in healthy adult subjects
Journal of Psychopharmacology · 2017
41
cited
A literature review on the pharmacological sensitivity of human evoked hyperalgesia pain models.
British Journal of Clinical Pharmacology · 2016
40
cited
Electrocardiogram Characteristics of Methadone and Buprenorphine Maintained Subjects
Journal of Addictive Diseases · 2008
36
cited
Demonstration of an anti‐hyperalgesic effect of a novel pan‐Trk inhibitor PF‐06273340 in a battery of human evoked pain models
British Journal of Clinical Pharmacology · 2018
35
cited
Fentanyl Utility Function: A Risk–Benefit Composite of Pain Relief and Breathing Responses
Anesthesiology · 2013
32
cited
The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia.
The Oncologist · 2019
31
cited
The use of a battery of pain models to detect analgesic properties of compounds: a two‐part four‐way crossover study
British Journal of Clinical Pharmacology · 2017
31
cited
Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Dose Almorexant, an Orexin Receptor Antagonist, in Healthy Elderly Subjects
Journal of Clinical Psychopharmacology · 2013
25
cited
Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans.
British Journal of Anaesthesia · 2019
24
cited
Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects.
British Journal of Clinical Pharmacology · 2016
22
cited
Responsiveness of electrical nociceptive detection thresholds to capsaicin (8 %)-induced changes in nociceptive processing
Experimental Brain Research · 2016
21
cited
Antinociceptive effects of high dose remifentanil in male methadone‐maintained patients
European Journal of Pain · 2008
20
cited
Commentary on the MID3 Good Practices Paper
CPT: Pharmacometrics & Systems Pharmacology · 2017
20
cited
Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans
European Neuropsychopharmacology · 2013
20
cited
Sotabase
Justin Luke | Researcher Profile | Sotabase | Sotabase